Open Beta
TREN
MetriLume
TREN

US marketsENTX

SEC-sourced researchBeta

ENTX

Entera Bio Ltd.

Company comparison ↗

Data passport

CIK
0001638097
Exchange
Nasdaq
Business activity
— · SIC 2836
Financial inputs
6/6
Filing date
Oct 6, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2024: 181,000.0000 USD; December 2025: 42,000.0000 USD181K USD0 USD0December 2024December 2025
ENTX · Exact amounts and source periods · USD
Period endRevenueFiling date
December 2024181,000.0000Mar 27, 2026
December 202542,000.0000Mar 27, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 202542,000.0000-11,439,000.0000-7,370,000.000015,993,000.00002,892,000.0000Mar 27, 2026
December 2024181,000.0000-9,541,000.0000-6,818,000.00009,390,000.00001,310,000.0000Mar 27, 2026

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenues$42KDecember 2025Mar 27, 202610-K
Previous period revenueRevenues$181KDecember 2024Mar 27, 202610-K
Net incomeNetIncomeLoss-$11.44MDecember 2025Mar 27, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$7.37MDecember 2025Mar 27, 202610-K
Total assetsAssets$15.99MDecember 2025Mar 27, 202610-K
Total liabilitiesLiabilities$2.89MDecember 2025Mar 27, 202610-K

New filings

Explore methodology ↗